

## Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707

Yoshinobu Maeda,<sup>1</sup> Hisakazu Nishimori,<sup>1</sup> Isao Yoshida,<sup>2</sup> Yasushi Hiramatsu,<sup>3</sup> Masatoshi Uno,<sup>4</sup> Yasufumi Masaki,<sup>5</sup> Kazutaka Sunami,<sup>6</sup> Taro Masunari,<sup>7</sup> Yuichiro Nawa,<sup>8</sup> Hiromichi Yamane,<sup>9</sup> Hiroshi Gomyo,<sup>10</sup> Tsutomu Takahashi,<sup>11</sup> Tomofumi Yano,<sup>12</sup> Keitaro Matsuo,<sup>13</sup> Koichi Ohshima,<sup>14</sup> Shigeo Nakamura,<sup>15</sup> Tadashi Yoshino<sup>16</sup> and Mitsune Tanimoto<sup>1</sup>

<sup>1</sup>Department of Hematology and Oncology, Okayama University Hospital; <sup>2</sup>Department of Hematologic Oncology, Shikoku Cancer Center, Ehime; <sup>3</sup>Department of Hematology and Oncology, Japanese Red Cross Society Himeji Hospital, Hyogo; <sup>4</sup>Department of Internal Medicine, Kaneda Hospital, Okayama; <sup>5</sup>Department of Hematology and Immunology, Kanazawa Medical University Hospital, Ishikawa; <sup>6</sup>Department of Hematology, National Hospital Organization Okayama Medical Center; <sup>7</sup>Department of Hematology, Chugoku Central Hospital, Hiroshima; <sup>8</sup>Department of Hematology, Ehime Prefectural Central Hospital, Ehime; <sup>9</sup>Department of Internal Medicine, Sumitomo Besshi Hospital, Ehime; <sup>10</sup>Department of Hematology, Hyogo Cancer Center, Hyogo; <sup>11</sup>Department of Hematology and Oncology, Shimane University Hospital; <sup>12</sup>Department of Hematology, Okayama Rosai Hospital; <sup>13</sup>Division of Molecular and Clinical Epidemiology, Aichi Cancer Center Research Institute, Nagoya; <sup>14</sup>Department of Pathology, School of Medicine, Kurume University, Fukuoka; <sup>15</sup>Department of Pathology and Clinical Laboratories, Nagoya University Hospital, and <sup>16</sup>Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Japan

©2017 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2017.167742

Received: March 10, 2017.

Accepted: September 20, 2017.

Pre-published: September 29, 2017.

Correspondence: yosmaeda@md.okayama-u.ac.jp

---

## Supplementary materials (Web appendix)

### Methods

#### *Eligibility criteria of PTCL 0707 study*

Eligibility requirements included stage II to IV lymphomas with bidimensionally measurable disease, age of 15 to 79 years, and Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. Patients were also required to have adequate organ function, as defined by a left ventricular ejection fraction (LVEF)  $\geq 50\%$ , serum creatinine level  $< 2.0$  mg/dL, serum bilirubin level  $< 2.0$  mg/dL, AST and ALT levels  $\leq 3$  times the upper limit of the normal range unless caused by lymphoma infiltration,  $\text{SpO}_2 \geq 90\%$  or  $\text{PaO}_2 \geq 60$  mmHg on room air, absolute neutrophil count (ANC)  $\geq 1 \times 10^9/\text{L}$ , and platelet count  $\geq 75 \times 10^9/\text{L}$  unless caused by lymphoma infiltration of the marrow or spleen. Exclusion criteria included pregnancy or lactation, a recent history of other malignant disease, a psychological disorder like schizophrenia, uncontrolled infections, severe complications (uncontrollable hypertension or diabetes mellitus, liver cirrhosis, interstitial pneumonia, pulmonary fibrosis), prior radiotherapy or chemotherapy except for steroid use up to 0.5 mg/kg, and seropositive for human immunodeficiency virus or hepatitis B surface antigen.

Staging procedures included a clinical examination, thoracic and abdominal computed tomography, blood count, bone marrow biopsy, and echocardiography with an evaluation of LVEF.